Health

Results: 2101-2112 of 9224

Broken String Biosciences Announces New Leadership to Drive Commercialization of INDUCE-seq® Platform for Gene Editing On- and Off-target Characterization

OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

PR Newswire associated0

Ozelle Launches Next-Generation AI + Complete Blood Morphology Solution at MEDICA 2025

Interlinked advances to next phase - CE-MDR approved dual-use solution for civilian and military healthcare

PR Newswire associated0

Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion

Clue Expands Wearable Integrations with Withings, Ultrahuman, WHOOP, Huawei, Polar, Fitbit, Noise and Luna, Unlocking Deeper Insights into Women’s Health

Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis

ONWARD Medical Receives FDA 510(k) Clearance Expanding ARC-EX System Indication for Home Use

ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline

Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)